Sunday, March 9, 2025
spot_img

NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

EDEN PRAIRIE, Minn., March 05, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced that it will participate in the upcoming Oppenheimer 35th Annual Healthcare Conference MedTech & Services Conference on Wednesday, March 19, 2025.

NeuroOne CEO Dave Rosa will host a virtual corporate presentation at 9:20 a.m. eastern time on Wednesday, March 19, 2025, followed by one-on-one meetings, which can be requested through Oppenheimer. To join live or view a replay of the webcast, please visit this link or the events page on NeuroOne’s investors relations website.

About NeuroOne
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

IR Contact
Chris Donovan
MZ Group – MZ North America
[email protected]
(914) 352-5853

Powered by SlickText.com

Hot this week

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease...

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented...

Kaldalón hf.: Annual General Meeting 3 April 2025

The Board of Directors of Kaldalón hf. hereby announces...

Changes in the Supervisory Board and Management Board of subsidiary

The membership of the Supervisory Board of Aktsiaselts Infortar...

Topics

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented...

Kaldalón hf.: Annual General Meeting 3 April 2025

The Board of Directors of Kaldalón hf. hereby announces...

Changes in the Supervisory Board and Management Board of subsidiary

The membership of the Supervisory Board of Aktsiaselts Infortar...

Holding(s) in Company

Standard Form TR-1 Standard form for notification of...

Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements

Ra’anana, Israel, March 07, 2025 (GLOBE NEWSWIRE)...
spot_img

Related Articles

Popular Categories

spot_img